|
|
作者：SCI天天读
SCI
12 May 2024
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature
(Journal of Clinical Oncology, IF: 45.30)
Annelot J.M. Meijer; Franciscus A. Diepstraten; Marc Ansari,; Eric Bouffet,; Archie Bleyer; Brice Fresneau; James I. Geller; Alwin D.R. Huitema; Per Kogner; Rudolf Maibach; Allison F. O’Neill; Vassilios Papadakis; Kaukab M. Rajput; Gareth J. Veal; Michael Sullivan; Marry M. van den Heuvel-Eibrink; and Penelope R. Brock
CORRESPONDENCE TO: m.m.vandenheuveleibrink@prinsesmaximacentrum.nl
PURPOSE 目的
Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL).
50%至70%接受顺铂治疗的儿童会出现听力损失。经过科学研究，美国食品药品监督管理局、欧洲药品管理局和英国药品和健康监管局最近批准了一种用于耳保护的静脉注射硫代硫酸钠（STS）儿科药物。为了向利益相关者介绍STS的临床实用性，本综述总结了关于全身STS的疗效、药代动力学（PK）和安全性的现有文献，以最大限度地减少顺铂导致的听力损失（CIHL）。
DESIGN 设计
A comprehensive narrative review is presented.
这是一篇全面的叙述性综述。
RESULTS 结果
Thirty-one articles were summarized. Overall, systemic STS effectively reduces CIHL in the preclinical and controlled clinical study settings, in both adults and children with cancer. The extent of CIHL reduction depends on the timing and dosing of STS in relation to cisplatin. Both preclinical and clinical data suggest that systemic STS may affect plasma platinum levels, but studies are inconclusive. Delayed systemic administration of STS, at 6 hours after the cisplatin infusion, does not affect cisplatin-induced inhibition of tumor growth or cellular cytotoxicity in the preclinical setting, nor affect cisplatin efficacy and survival in children with localized disease in the clinical setting.
本综述总结了三十一篇文章。总体而言，在成人癌症患者和儿童癌症患者的临床前和对照临床研究环境中，全身STS有效降低了CIHL。CIHL减少的程度取决于STS相对于顺铂的给药时间和给药剂量。临床前研究数据和临床数据都表明，全身STS可能会影响血浆铂类药物水平，但研究尚无定论。在顺铂输注6小时后延迟全身给药STS，在临床前环境中不会影响顺铂诱导的抑制肿瘤生长或细胞毒性，在临床环境中也不会影响罹患局部恶性肿瘤的儿童的应用顺铂的疗效和生存率。
CONCLUSION 结论
Systemic administration of STS effectively reduces the development and degree of CIHL in both the preclinical and clinical settings. More studies are needed on the PK of STS and cisplatin drug combinations, the efficacy and safety of STS in patients with disseminated disease, and the ability of STS to prevent further deterioration of pre-established hearing loss.
在临床前和临床环境中，STS的全身给药有效地降低了CIHL的发展和严重程度。需要在STS和顺铂药物组合的PK、STS在转移性肿瘤患者中的疗效和安全性以及应用STS预防听力损失进一步恶化的能力等方面进行更多的研究。
喜欢SCI天天读的理由
陪您一起学习SCI医学论文
每天5分钟，让自己的英语牛逼起来
特殊福利让您惊喜连连
复制链接或点击原文链接，即可下载SCI原文
W215N02
链接：https://pan.baidu.com/s/1yK8d6J87MqJEdvXKSx77kQ?pwd=6bif
提取码：6bif |
|
